首页> 美国政府科技报告 >Dissecting the Mechanisms of Drug Resistance in BRCA1/2-Mutant Breast Cancers.

【24h】

Dissecting the Mechanisms of Drug Resistance in BRCA1/2-Mutant Breast Cancers.

机译：剖析BRCa1 / 2突变乳腺癌的耐药机制。

获取原文

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
D'Andrea, A.;
展开▼
作者单位

展开▼
年度 2017
页码 1-69
总页数 69
原文格式 PDF
正文语种 eng
中图分类
关键词
Drug resistance; Breast cancer;

机译：耐药性;乳腺癌;

相似文献

外文文献
中文文献
专利

1. 231例乳腺癌患者乳腺癌易感基因 BRCA1 的突变检测及分析 [J] . 王曦, 杨名添, 方, 癌症（英文版） . 2001,第009期
2. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2020,第5期

机译：抗PARP抑制剂或铂化疗的逆转和非逆转机制在BRCA1 / 2-突变转移乳腺癌中
3. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. [J] . Miyamoto Kazuaki, Fukutomi Takashi, Asada Kiyoshi, Japanese journal of clinical oncology. . 2002,第3期

机译：促进人甲基化和转录后机制，以减少散发性人乳腺癌中BRCA1的免疫反应性。
4. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer [J] . ter Brugge Petra, Kristel Petra, van der Burg Eline, Journal of the National Cancer Institute . 2016,第11期

机译：BRCA1缺陷型乳腺癌患者异种移植模型中抗药性的机制
5. Tunable Biomaterials to Identify Mechanisms of ECM-Mediated Drug Resistance in Breast Cancer [C] . Alyssa D. Schwartz, Lauren E. Barney, Lauren E. Jansen, Society for Biomaterials annual meeting and exposition . 2018

机译：可调谐生物材料，以识别乳腺癌中ECM介导的耐药性机制
6. Mechanisms Governing Early Dissemination in Her2+ Breast Cancers. [D] . Harper, Kathryn. 2016

机译：在Her2 +乳腺癌中控制早期传播的机制。
7. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity [O] . Mariusz L. Hartman, Malgorzata Sztiller-Sikorska, Anna Gajos-Michniewicz, 2020

机译：黑色素瘤对BRAF和MEK抑制剂抗性的解剖机制揭示了遗传和非遗传的患者和药物特异性变化和显着的表型可塑性
8. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer [O] . Adrienne G. Waks, Ofir Cohen, Bose Kochupurakkal, 2019

机译：抗PARP抑制剂或铂化疗的抗抗逆转机制BRCA1 / 2-突变转移乳腺癌

Dissecting the Mechanisms of Drug Resistance in BRCA1/2-Mutant Breast Cancers.

著录项

引文网络

相似文献

相关主题

期刊订阅